HD Industry Update

IXICO PLC

("IXICO or the "Company")

PIPELINE UPDATE

13 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, notes the continued evolution of the Huntington's disease (HD) landscape, an area of particular interest.

HD remains one of the most active and well-funded areas of neuroscience drug development, alongside Alzheimer's and Parkinson's disease. Investment continues across both established and emerging therapeutic approaches, supporting an increasingly diversified pipeline of clinical programmes for IXICO and hope for patients.

As announced in its Half Year Results, IXICO secured £8.0 million of new HD programme awards by new and existing clients during the first half of FY26. Since the half year, two existing HD programmes supported by IXICO have been discontinued by their sponsors, reducing the Company's contracted order book by approximately £1.5 million over the next two financial years. Following these changes, IXICO's order book remains 21% above the FY25 year-end level, a solid increase reflecting the above described positive dynamics.

While programme descoping is always a sad moment for the medical community, it is a normal feature of clinical drug development and is reflected in the Company's forecasting together with the newer incoming pipeline opportunities across a broad array of neurology indications and recently created "TechBio" channels.

The Board confirms that its recently upgraded FY26 and its FY27 revenue guidance remain unchanged and continues to expect the Company to meet or exceed market expectations.

Ends

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.

The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.